저자의 연구 키워드

저자의 연구 키워드

#5-HT3 receptor antagonist

#갑상선 전이암

#갑상선기능저하증

#공장

#발생률

#약제유발

#원시신경외배엽종양

#하시모토 갑상선염

#항암화학요법

#Adenoid cystic carcinoma

#Adjuvant chemoradiotherapy

#Adjuvant chemotherapy

#Administration

#Albumin-bound paclitaxel

#Angiogenesis

#Antibody-drug conjugates

#Antiemetics

#Antineoplastic agents

#Antitumor

#Aromatase inhibitors

#Arthritis

#Asian

#Asians

#ATR inhibitor

#Atypical mycobacterium infection

#Awareness

#Bayesian network

#bcl-2

#Belotecan

#Benign

#Biliary tract neoplasms

#Biological markers

#Blood platelets

#Brain metastasis

#BRCA1/2 mutation

#Breast neoplasms

#Breast-conserving surgery

#CA 19-9 antigen

#Cancer evolution

#Carcinoembryonic antigen

#CDK4/6 inhibitor

#Cell cycle progression

#Chemoradiotherapy

#Chemotherapy

#Cisplatin

#Clinical Trial

#Colorectal neoplasms

#Copy number variation

#Cost analysis

#Cyclooxygenase 2

#Cyclooxygenase-2

#Desmoplastic small round cell tumor

#Diabetes mellitus

#Disseminated

#DNA damage

#Dolasetron mesylate

#Drug Screening Assays

#Drug therapy

#Endocrine therapy

#Eribulin

#Exemestane

#Failure to imatinib

#First-line treatment

#Fluorescence

#Fluorescence in situ hybridization

#Fulvestrant

#Fusion gene

#Gastric Cancer

#Gastrointestinal stromal tumors

#Gemcitabine

#Genetic polymorphism

#Gonadotropin-releasing hormone

#HER2

#HER-2/neu

#HER2-negative

#Hereditary cancer

#Hormone receptor positive

#Hormone receptor-positive

#Hormone resistance

#Human breast cancer

#Hypothyroidism

#Immunohistochemistry

#In Situ Hybridization

#Incidence

#Inflammation

#Insulin

#Interleukin-1beta

#Investigator-initiated trials

#Ixabepilone

#Jejunum

#Ki-67 antigen

#Korea

#Korean

#Korean Cancer Study Group

#Koreans

#KX-01

#Leptin

#Leptomeningeal Metastases

#Letrozole

#Leukocytes

#Long-acting granulocyte-colony stimulating factor

#Lymph node excision

#Lymph nodes

#Management access program

#Mediastinal lymph node

#Metastasis

#Metastatic breast cancer

#Metformin

#Microsatellite instability

#Microtubules

#Mitotic catastrophe

#Mortality

#Musculoskeletal Pain

#Mutation

#Mycobacterium abscessus

#Nausea

#Neoadjuvant chemotherapy

#Neoadjuvant therapy

#Neoplasm metastasis

#Neoplasms

#Neuroectodermal Tumors

#Neutropenia

#Next-generation sequencing

#Nomograms

#Non-small cell lung carcinoma

#Obesity

#Ondansetron

#Oral

#Ovariectomy

#Overall survival

#Oxaliplatin

#p53

#Paclitaxel

#Palbociclib

#Pancreatectomy

#Pancreatic neoplasms

#PARP inhibitor

#Patients

#Pattern of care study

#Perception

#P-glycoprotein

#Pharmacokinetics

#Pharmacology

#Phase 1

#Phase II trial

#Phase III

#Phase IV clinical trial

#Precision diagnosis

#Precision medicine

#Premenopause

#Progesterone receptors

#Prognosis

#Prognostic Factor

#Progression-free survival

#Pulmonary nodule

#Radiation therapy

#Radiotherapy

#Regorafenib

#Replication catastrophe

#Replication stress

#Response

#Reverse transcriptase polymerase chain reaction

#Rheumatoid

#RNA stability

#S-1

#Safety

#Segmental mastectomy

#Sensitivity and Specificity

#Sequencing

#Sinusoidal obstruction syndrome

#Smad3

#Soft tissue infections

#Solid Tumor

#Splenic artery

#Splenomegaly

#Src kinase inhibitor

#Statin

#Stomach neoplasms

#Sunitinib

#Survival analysis

#Synergism

#Talazoparib

#Tamoxifen

#Targeted gene

#Therapeutic Use

#Time-to-treatment

#Transforming growth factor beta

#Transforming growth factor beta1

#Trastuzumab

#Trastuzumab deruxtecan

#Triple negative breast neoplasms

#Triple-negative breast carcinoma

#Tristetraprolin

#TSU-68

#Tumor biomarker

#Tumor embolism

#Tumor suppressor protein p53

#Vascular endothelial growth factor

#Volition

#Vomiting